Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and/or 13q14.

[1]  E. Giné,et al.  Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. , 2012, Cancer research.

[2]  M. Raffeld,et al.  The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index , 2012, Haematologica.

[3]  E. Giné,et al.  Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease , 2012, Leukemia.

[4]  F. Mancini,et al.  Behind the scenes of non‐nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes , 2012, British journal of haematology.

[5]  R. Lai,et al.  Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis , 2011, Haematologica.

[6]  R. Siebert,et al.  Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma , 2010, Genes, chromosomes & cancer.

[7]  S. Fernández de Mattos,et al.  Molecular biology of mantle cell lymphoma: from profiling studies to new therapeutic strategies. , 2009, Blood reviews.

[8]  A. Rosenwald,et al.  Molecular outcome prediction in mantle cell lymphoma. , 2009, Future oncology.

[9]  E. Hoster,et al.  Improvement of overall survival in advanced stage mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Campo,et al.  Advances in the understanding of mantle cell lymphoma , 2008, British journal of haematology.

[11]  E. Campo,et al.  Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics , 2007, Nature Reviews Cancer.

[12]  E. Giné,et al.  Leukemic involvement is a common feature in mantle cell lymphoma , 2007, Cancer.

[13]  L. Staudt,et al.  Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Catovsky,et al.  A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. , 2003, Blood.

[15]  G. Salles,et al.  Mantle cell lymphoma: a retrospective study of 121 cases , 1998, Leukemia.

[16]  P. Cohen,et al.  Bone marrow and peripheral blood involvement in mantle cell lymphoma , 1998, British journal of haematology.

[17]  A. López-Guillermo,et al.  Mantle cell lymphoma , 1998, Cancer.

[18]  R. Gascoyne,et al.  Mantle cell lymphoma: a clinicopathologic study of 80 cases. , 1997, Blood.